Skip to main content
. 2022 Sep 27;2022(9):CD014638. doi: 10.1002/14651858.CD014638.pub2

Aggarwal 2018.

Methods Method of randomisation not clear.
Participants 105 survivors of paediatric ALL or Hodgkin lymphoma (mean age at follow‐up 27.7 years; N = 47 females and N = 58 males; stage of disease at diagnosis nm) treated with doxorubicin (cumulative dose 100 to 360 mg/m2; peak dose (i.e. maximal dose received in 1 week) nm; infusion duration nm). Prior anthracycline therapy nm. Prior cardiac radiotherapy nm. Prior cardiac dysfunction nm.
Interventions Dexrazoxane (ratio to doxorubicin 10:1; timing in relation to anthracycline nm) (N = 57) versus no cardioprotective intervention (N = 48).
Outcomes Heart failure (i.e. different abnormalities on speckle tracking echocardiography); in the abstract no dichotomous results were provided.
Notes Unclear if this is an ongoing or completed study. Length of follow‐up 16.5 years since cancer diagnosis. Mean cumulative anthracycline dose in the dexrazoxane group was 282 mg/m2 and in the control group 275 mg/m2. Mean age at echocardiogram of the dexrazoxane group was 27.3 years and of the control group 28.1 years.